Clinical Trials in Michigan

Showing 1301-1320 of 7,755 trials

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.

Non Small Cell Lung CancerSolid Tumors, AdultLung Cancer+1 more

Tango Therapeutics, Inc.126 participantsStarted Jun 2023

Santa Monica, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +10 more locations

COMPLETEDPhase 283 miles

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

NCT05424276

This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. For more information, visit our website: www.the201trial.com

Parkinson Disease

ABLi Therapeutics, Inc.137 participantsStarted May 2023

Scottsdale, Arizona, United States • Little Rock, Arkansas, United States • Reseda, California, United States +25 more locations

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

Find Trials by Condition in Michigan

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

The Synergy Disc To Anterior Cervical Discectomy and Fusion

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Study of AVZO-021 in Patients With Advanced Solid Tumors

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study

ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MARGetuximab Or Trastuzumab (MARGOT)

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Pharmacogenomics for Better Treatment of Fungal Infections in Cancer